For years, confirming a diagnosis of Alzheimer’s disease required expensive brain scans or an uncomfortable spinal tap. That is now changing.
In 2025, the U.S. Food and Drug Administration (FDA) approved the first blood test that can help doctors detect early signs of Alzheimer’s disease. This breakthrough may make diagnosis faster, easier, and more accessible for families, especially here in Maine where Alzheimer’s affects tens of thousands of older adults.
How the New Alzheimer’s Blood Test Works
The new test, called Lumipulse, with similar versions such as Elecsys, looks for two key proteins in the blood: amyloidand tau. These proteins are linked to changes in the brain that occur in Alzheimer’s disease.
By measuring how much of each protein is present, doctors can estimate whether the brain is likely developing the plaques and tangles associated with Alzheimer’s.
The test requires only a standard blood draw and can often be performed at a clinic or hospital lab.
Why This Matters for Maine Families
Alzheimer’s is one of the leading causes of dementia in Maine, with more than 29,000 residents aged 65 and olderliving with the disease.
For many families, diagnosis comes late, sometimes after years of uncertainty or confusion.
A simple blood test could make early detection much more practical, helping Mainers:
- Get answers sooner when memory changes begin
- Explore treatment or clinical trial options
- Start meaningful conversations about care preferences and long-term plans
- Take legal and financial steps while a loved one can still participate in decisions
Accuracy and Limitations
In clinical studies, the new blood tests correctly identified Alzheimer’s-related brain changes about 90 to 97 percent of the time when compared with PET scans or spinal fluid testing.
However, this is not a stand-alone diagnostic test. Doctors still rely on:
- Medical history and physical exams
- Cognitive or memory testing
- Imaging or additional lab work if needed
The test is recommended for adults age 55 and older who already have symptoms such as forgetfulness, confusion, or difficulty managing daily tasks. It is not designed for general screening in healthy individuals.
Coverage through Medicare or MaineCare is still developing, and availability may vary by clinic or provider.
Why Early Detection Matters for Long-Term Care Planning
An early Alzheimer’s diagnosis can be difficult to hear, but it also creates an opportunity to plan.
Families can begin to:
- Consider care options such as in-home support, assisted living, or memory care
- Review eligibility for MaineCare (the state’s Medicaid program)
- Update estate plans, powers of attorney, and health care directives
- Prepare financially for future needs and protect assets responsibly
Early awareness gives families time to make decisions with less stress and more clarity.
Looking Ahead
The approval of the Alzheimer’s blood test represents a major step forward in dementia care. It gives patients and families a clearer path to understanding what is happening and what comes next.
For Maine families, it reinforces an important message: planning early is the best protection.
If you or a loved one are experiencing memory changes, talk with your health care provider about whether a blood test for Alzheimer’s could help bring clarity, and contact Aging in Maine to start a proactive conversation about long-term care planning and support.
💙 Plan today for peace of mind tomorrow.
